Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Metabolomics of Diapause in Aedes albopictus (Study ST000722)

C18 NEGATIVE ION MODE (Analysis AN001131)

Metabolite	Structure	F1	F2
plasmenyl-PE 36:5; [M-H]-@6.33	ME203245	1.65	0.35
lysoPE 22:6; [M-H]-@1.32	ME203236	0.78	1.22
PC 37:3; [M-Ac-H]-@6.88	ME203126	0.53	1.47
plasmenyl-PE 40:6; [M-H]-@7.25	ME203252	0.61	1.39
PG 32:2; [M-H]-@4.71	ME203185	1.05	0.95
PE 40:1; [M-H]-@8.52	ME203177	1.05	0.95
PE 35:2; [M-H]-@6.74	ME203158	1.05	0.95
PE 34:1; [M-H]-@6.88	ME203152	1.05	0.95
PC 36:1; [M-Ac-H]-@7.58	ME203121	1.05	0.95
PC 34:1; [M-Ac-H]-@6.91	ME203113	1.05	0.95
CerP 34:1; [M-H]-@5.95	ME203081	1.05	0.95
CL 70:6; [M-2H](2-)@9.05	ME203078	1.05	0.95
plasmenyl-PE 38:5; [M-H]-@6.86	ME203250	1.07	0.93
PI 38:6; [M-H]-@4.91	ME203209	1.07	0.93
PI 36:4; [M-H]-@5.00	ME203204	1.07	0.93
PE 40:8; [M-H]-@6.03	ME203181	1.07	0.93
PE 38:6; [M-H]-@6.16	ME203175	1.07	0.93
PE 38:1; [M-H]-@8.01	ME203171	1.07	0.93
PE 34:4; [M-H]-@5.52	ME203155	1.07	0.93
PC 36:6; [M-Ac-H]-@5.43	ME203125	1.07	0.93
PC 34:6; [M-Ac-H]-@4.72	ME203118	1.07	0.93
CL 70:5; [M-2H](2-)@9.27	ME203077	1.07	0.93
PC 30:0; [M-Ac-H]-@6.10	ME203101	1.07	0.93
PS 40:9; [M-H]-@4.46	ME203225	1.06	0.94
PI 38:3; [M-H]-@6.05	ME203206	1.06	0.94
PI 36:5; [M-H]-@4.67	ME203205	1.06	0.94
PI 36:2; [M-H]-@5.84	ME203202	1.06	0.94
PG 34:1; [M-H]-@5.86	ME203187	1.06	0.94
PE 40:4; [M-H]-@7.58	ME203178	1.06	0.94
PE 36:5; [M-H]-@5.88	ME203166	1.06	0.94
PE 36:2; [M-H]-@7.02	ME203163	1.06	0.94
PE 36:1; [M-H]-@7.45	ME203162	1.06	0.94
PC 38:4; [M-Ac-H]-@6.99	ME203131	1.06	0.94
FFA(22:0)	ME203090	1.06	0.94
PC 31:2; [M-Ac-H]-@5.40	ME203104	1.06	0.94
PS 36:4; [M-H]-@5.01	ME203218	1.10	0.90
PS 34:3; [M-H]-@4.80	ME203214	1.10	0.90
plasmenyl-PE 34:1; [M-H]-@7.14	ME203239	1.10	0.90
PE 34:3; [M-H]-@5.96	ME203154	1.10	0.90
PE 32:3; [M-H]-@5.32	ME203149	1.10	0.90
PC 40:2; [M-Ac-H]-@8.44	ME203136	1.10	0.90
CL 64:4; [M-2H](2-)@8.62	ME203071	1.10	0.90
PC 38:6; [M-Ac-H]-@6.12	ME203133	1.10	0.90
PS 36:2; [M-H]-@5.98	ME203216	1.11	0.89
PG 36:3; [M-H]-@5.51	ME203192	1.11	0.89
PE 34:5; [M-H]-@5.15	ME203156	1.11	0.89
FFA(24:0)	ME203094	1.11	0.89
PC 30:1; [M-Ac-H]-@5.59	ME203102	1.11	0.89
PI 34:2; [M-H]-@5.15	ME203200	1.08	0.92
PI 34:1; [M-H]-@5.71	ME203199	1.08	0.92
PE 42:1; [M-H]-@9.00	ME203182	1.08	0.92
PE 32:2; [M-H]-@5.76	ME203148	1.08	0.92
PC 34:3; [M-Ac-H]-@5.91	ME203115	1.08	0.92
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.87	ME203098	1.08	0.92
CL 70:7; [M-2H](2-)@8.84	ME203079	1.08	0.92
lysoPE 22:5; [M-H]-@1.54	ME203235	1.08	0.92
PS 38:4; [M-H]-@5.96	ME203220	1.09	0.91
PS 32:1; [M-H]-@5.14	ME203210	1.09	0.91
plasmenyl-PE 38:1; [M-H]-@8.35	ME203246	1.09	0.91
PE 38:3; [M-H]-@7.29	ME203173	1.09	0.91
PE 38:2; [M-H]-@7.60	ME203172	1.09	0.91
PE 36:0; [M-H]-@7.96	ME203161	1.09	0.91
PE 35:1; [M-H]-@7.14	ME203157	1.09	0.91
PC 36:2; [M-Ac-H]-@6.98	ME203122	1.09	0.91
PC 32:1; [M-Ac-H]-@6.27	ME203106	1.09	0.91
PC 32:2; [M-Ac-H]-@5.73	ME203107	1.09	0.91
PC 33:1; [M-Ac-H]-@6.60	ME203111	1.17	0.83
plasmenyl-PE 34:3; [M-H]-@6.42	ME203241	1.17	0.83
FFA(20:2)	ME203088	1.20	0.80
PC 40:6; [M-Ac-H]-@6.88	ME203139	1.18	0.82
PG 33:0; [M-H]-@6.02	ME203186	1.18	0.82
PE 30:0; [M-H]-@6.20	ME203143	1.19	0.81
plasmenyl-PE 36:2; [M-H]-@7.31	ME203242	1.19	0.81
PS 36:3; [M-H]-@5.48	ME203217	1.12	0.88
PS 34:2; [M-H]-@5.26	ME203213	1.12	0.88
PS 34:1; [M-H]-@5.83	ME203212	1.12	0.88
PG 38:5; [M-H]-@5.55	ME203196	1.12	0.88
PG 36:2; [M-H]-@5.98	ME203191	1.12	0.88
PE 40:7; [M-H]-@6.45	ME203180	1.12	0.88
PC 32:3; [M-Ac-H]-@5.26	ME203108	1.12	0.88
CL 72:7; [M-2H](2-)@9.10	ME203080	1.12	0.88
PC 30:2; [M-Ac-H]-@5.02	ME203103	1.12	0.88
PS 32:2; [M-H]-@4.60	ME203211	1.13	0.87
plasmenyl-PE 32:1; [M-H]-@6.66	ME203237	1.13	0.87
PE 35:3; [M-H]-@6.27	ME203159	1.13	0.87
PE 33:0; [M-H]-@7.01	ME203150	1.13	0.87
PC 42:1; [M-Ac-H]-@9.45	ME203141	1.13	0.87
PC 42:2; [M-Ac-H]-@9.04	ME203142	1.13	0.87
plasmenyl-PE 34:2; [M-H]-@6.77	ME203240	1.14	0.86
PC 28:0; [M-Ac-H]-@5.40	ME203099	1.14	0.86
PE 33:2; [M-H]-@6.06	ME203151	1.14	0.86
PS 38:5; [M-H]-@5.45	ME203221	1.15	0.85
PC 28:1; [M-Ac-H]-@4.81	ME203100	1.15	0.85
PC 32:4; [M-Ac-H]-@4.82	ME203109	1.15	0.85
PS 40:10; [M-H]-@4.02	ME203223	1.03	0.97
PI 32:1; [M-H]-@5.01	ME203198	1.03	0.97
PG 32:1; [M-H]-@5.22	ME203184	1.03	0.97
PE 32:1; [M-H]-@6.25	ME203147	1.03	0.97
PE 30:2; [M-H]-@5.08	ME203145	1.03	0.97
PC 38:3; [M-Ac-H]-@7.31	ME203130	1.03	0.97
PC 38:2; [M-Ac-H]-@7.75	ME203129	1.03	0.97
PC 34:4; [M-Ac-H]-@5.56	ME203116	1.03	0.97
FFA(22:1)	ME203091	1.03	0.97
FFA(20:1)	ME203087	1.03	0.97
FFA(16:0)	ME203082	1.03	0.97
FFA(18:2)	ME203085	1.03	0.97
PS 38:6; [M-H]-@4.95	ME203222	1.04	0.96
plasmenyl-PE 36:4; [M-H]-@6.70	ME203244	1.04	0.96
plasmenyl-PE 38:4; [M-H]-@7.33	ME203249	1.04	0.96
plasmenyl-PE 38:2; [M-H]-@7.97	ME203247	1.01	0.99
PI 36:3; [M-H]-@5.31	ME203203	1.01	0.99
PC 38:7; [M-Ac-H]-@5.67	ME203134	1.01	0.99
CL 66:5; [M-2H](2-)@8.69	ME203073	1.01	0.99
PC 38:1; [M-Ac-H]-@8.27	ME203128	1.01	0.99
PS 36:1; [M-H]-@6.40	ME203215	1.02	0.98
PI 38:4; [M-H]-@5.88	ME203207	1.02	0.98
PE 37:4; [M-H]-@6.72	ME203170	1.02	0.98
PE 36:4; [M-H]-@6.28	ME203165	1.02	0.98
PC 38:5; [M-Ac-H]-@6.47	ME203132	1.02	0.98
PC 34:5; [M-Ac-H]-@5.27	ME203117	1.02	0.98
lysoPE 17:0; [M-H]-@2.05	ME203228	1.02	0.98
FFA(18:1)	ME203084	1.02	0.98
FFA(24:1)	ME203095	1.02	0.98
PI 38:5; [M-H]-@5.31	ME203208	1.00	1.00
PI 34:3; [M-H]-@4.67	ME203201	1.00	1.00
PG 36:5; [M-H]-@4.87	ME203194	1.00	1.00
PE 40:5; [M-H]-@7.18	ME203179	1.00	1.00
PE 36:6; [M-H]-@5.50	ME203167	1.00	1.00
PE 35:4; [M-H]-@6.09	ME203160	1.00	1.00
PE 34:2; [M-H]-@6.43	ME203153	1.00	1.00
FFA(18:0)	ME203083	1.00	1.00
PC 34:2; [M-Ac-H]-@6.33	ME203114	1.00	1.00
plasmenyl-PE 34:0; [M-H]-@7.33	ME203238	0.99	1.01
PE 36:3; [M-H]-@6.58	ME203164	0.99	1.01
PC 40:4; [M-Ac-H]-@7.56	ME203137	0.99	1.01
PC 36:5; [M-Ac-H]-@5.84	ME203124	0.99	1.01
PC 36:3; [M-Ac-H]-@6.53	ME203123	0.99	1.01
PC 35:1; [M-Ac-H]-@7.31	ME203119	0.99	1.01
FFA(20:0)	ME203086	0.99	1.01
lysoPE 16:0; [M-H]-@1.64	ME203226	0.99	1.01
PG 34:2; [M-H]-@5.34	ME203188	0.96	1.04
PE 38:5; [M-H]-@6.55	ME203174	0.96	1.04
PE 32:0; [M-H]-@6.81	ME203146	0.96	1.04
CL 70:4; [M-2H](2-)@9.43	ME203076	0.96	1.04
PC 33:2; [M-Ac-H]-@6.10	ME203112	0.96	1.04
PS 40:8; [M-H]-@4.88	ME203224	0.98	1.02
PG 36:6; [M-H]-@4.46	ME203195	0.98	1.02
CL 64:3; [M-2H](2-)@8.90	ME203070	0.98	1.02
PE 37:2; [M-H]-@7.33	ME203169	0.98	1.02
PG 38:6; [M-H]-@5.14	ME203197	0.97	1.03
PG 34:3; [M-H]-@4.89	ME203189	0.97	1.03
PG 32:0; [M-H]-@5.76	ME203183	0.97	1.03
PE 38:7; [M-H]-@5.66	ME203176	0.97	1.03
PC 35:2; [M-Ac-H]-@6.75	ME203120	0.97	1.03
FFA(20:4) Arachidonic acid	ME203089	0.97	1.03
lysoPE 20:3; [M-H]-@1.64	ME203233	0.97	1.03
lysoPE 20:4; [M-H]-@1.33	ME203234	0.86	1.14
lysoPE 18:1; [M-H]-@1.82	ME203230	0.94	1.06
CL 66:4; [M-2H](2-)@8.93	ME203072	0.94	1.06
lysoPE 16:1; [M-H]-@1.17	ME203227	0.94	1.06
PS 36:5; [M-H]-@4.74	ME203219	0.93	1.07
plasmenyl-PE 40:4; [M-H]-@7.83	ME203251	0.93	1.07
lysoPE 18:0; [M-H]-@2.49	ME203229	0.93	1.07
PG 36:0; [M-H]-@6.90	ME203190	0.93	1.07
CL 68:4; [M-2H](2-)@9.19	ME203074	0.92	1.08
PG 36:4; [M-H]-@5.18	ME203193	0.92	1.08
lysoPE 18:3; [M-H]-@1.02	ME203232	0.91	1.09
PC 32:0; [M-Ac-H]-@6.83	ME203105	0.91	1.09
plasmenyl-PE 38:3; [M-H]-@7.56	ME203248	0.89	1.11
PC 40:7; [M-Ac-H]-@6.37	ME203140	0.90	1.10
CL 68:5; [M-2H](2-)@8.99	ME203075	0.90	1.10
lysoPE 18:2; [M-H]-@1.35	ME203231	0.90	1.10
FFA(22:2)	ME203092	1.47	0.53
FFA(22:3)	ME203093	1.45	0.55
PC 40:1; [M-Ac-H]-@8.89	ME203135	1.24	0.76
PE 30:1; [M-H]-@5.60	ME203144	1.23	0.77
PE 37:1; [M-H]-@7.66	ME203168	1.23	0.77
plasmenyl-PE 42:5; [M-H]-@7.93	ME203253	1.26	0.74
plasmenyl-PE 36:3; [M-H]-@7.02	ME203243	1.28	0.72
PC 37:4; [M-Ac-H]-@6.66	ME203127	1.27	0.73
PC 40:5; [M-Ac-H]-@7.22	ME203138	1.27	0.73
FFA(24:3)	ME203097	1.38	0.62
PC 33:0; [M-Ac-H]-@7.05	ME203110	1.30	0.70
FFA(24:2)	ME203096	1.33	0.67
plasmenyl-PE 42:6; [M-H]-@7.82	ME203254	1.33	0.67

Factors:

F1	Diapause:Diapause
F2	Diapause:Non-Diapause

Data matrix